Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes

• Published in: Journal of the American College of Cardiology Vol. 65; no. 15; pp. 1539 - 1548
• Main Authors: Bangalore, Sripal, Breazna, Andrei, DeMicco, David A., Wun, Chuan-Chuan, Messerli, Franz H.
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 21.04.2015; Elsevier Limited
• Subjects: Cardiology; Cardiovascular; Cardiovascular disease; cardiovascular outcomes; Cholesterol; Confidence intervals; Heart attacks; LDL cholesterol; Low density lipoprotein; Patients; Statins; variability; cardiovascular outcomes; LDL cholesterol; CV; ASV; LDL-C; CAD; HR; VIM; variability; MI; coronary artery disease; average successive variability; low-density lipoprotein cholesterol; myocardial infarction; variation independent of mean; hazard ratio; coefficient of variation
• DOI: 10.1016/j.jacc.2015.02.017
• ISSN: 0735-1097

Studies demonstrate that lowering low-density lipoprotein cholesterol (LDL-C) using a statin is associated with significant reduction in cardiovascular events. Whether visit-to-visit variability in LDL-C levels affects cardiovascular outcomes is unknown. This study sought to evaluate the role of visit-to-visit variability in LDL-C levels on cardiovascular outcomes. We evaluated patients with coronary artery disease and LDL-C <130 mg/dl enrolled in the TNT (Treating to New Targets) trial, randomly assigned to receive atorvastatin 80 mg/day versus 10 mg/day and with at least one post-baseline measurement of LDL-C. Visit-to-visit LDL-C variability was evaluated from 3 months into random assignment through the use of various measurements of LDL-C variability: SD, average successive variability (ASV), coefficient of variation, and variation independent of mean, with the first 2 measurements used as the primary measurements. Primary outcome was any coronary event, and secondary outcomes were any cardiovascular event, death, myocardial infarction, or stroke. Among 9,572 patients, SD and ASV were significantly lower with atorvastatin 80 mg/day versus 10 mg/day (SD: 12.03 ± 9.70 vs. 12.52 ± 7.43; p = 0.005; ASV: 12.84 ± 10.48 vs. 13.76 ± 8.69; p < 0.0001). In the adjusted model, each 1-SD increase in LDL-C variability (by ASV) increased the risk of any coronary event by 16% (hazard ratio [HR]: 1.16; 95% confidence interval [CI]: 1.10 to 1.23; p < 0.0001), any cardiovascular event by 11% (HR: 1.11; 95% CI: 1.07 to 1.15; p < 0.0001), death by 23% (HR: 1.23; 95% CI: 1.14 to 1.34; p < 0.0001), myocardial infarction by 10% (HR: 1.10; 95% CI: 1.02 to 1.19; p = 0.02), and stroke by 17% (HR: 1.17; 95% CI: 1.04 to 1.31; p = 0.01), independent of treatment effect and achieved LDL-C levels. Results were largely consistent when adjusted for medication adherence. In subjects with coronary artery disease, visit-to-visit LDL-C variability is an independent predictor of cardiovascular events.